

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

FORM 8-K

**Current Report
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported): **May 25, 2017**

ADAPTIMMUNE THERAPEUTICS PLC

(Exact name of registrant as specified in its charter)

England and Wales
(State or other jurisdiction of
incorporation)

1-37368
(Commission File Number)

Not Applicable
(IRS Employer Identification No.)

**101 Park Drive, Milton Park
Abingdon, Oxfordshire OX14 4RY
United Kingdom**
(Address of principal executive offices, including zip code)

(44) 1235 430000
(Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Item 1.01. Entry into a Material Definitive Agreement.

On May 25, 2017, Adaptimmune Therapeutics plc (the "Company" or "Adaptimmune") entered into an agreement for lease with MEPC Milton Park No. 1 Limited and MEPC Milton Park No. 2 Limited ("MEPC") for the lease of a building of approximately 46,000 square feet at Milton Park, Oxfordshire, U.K (the "Premises"). Following the completion of landlords' works, the Company will enter into a lease with MEPC of the Premises, which will provide additional laboratory and office space. The Lease has a 22-year term with break options exercisable by the Company on the fifth anniversary of the Lease commencement date and at approximately five yearly intervals thereafter. The rent payable under the Lease will be approximately \$279,930 (£218,580 translated at a rate of 1 GBP = 1.28068 USD) for the first five months and then approximately \$559,861 (£437,161) per year thereafter subject to reviews at approximately five yearly intervals.

Item 8.01 Other Events.

On May 26, 2017, the Company issued a press release announcing an oral presentation, as well as four trials in progress posters, at the 2017 ASCO annual meeting in Chicago, Illinois on June 2 through June 6, 2017. During an oral presentation scheduled for June 5th, Dr. Sandra P. D'Angelo of the Memorial Sloan Kettering Cancer Center will present a full update on Cohorts 1, 2, 3, and 4 from Adaptimmune's ongoing study of NY-ESO SPEAR T-cells in patients with synovial sarcoma. In the same press release, the Company also announced that it will host a webinar / teleconference on June 6th from 8:00—9:00 AM EDT (1:00—2:00 PM BST) to discuss this updated synovial sarcoma clinical data. Call in details and the webinar link will be made available in the Investors section of Adaptimmune's website (<http://www.adaptimmune.com>) and will also be provided in a subsequent ASCO press release on June 5th. The text of the press release is attached as Exhibit 99.1 and is incorporated by reference herein.

The information contained in Item 8.01 of this Form 8-K, including the attached Exhibit 99.1, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or incorporated by reference in any filing made by the Company under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by the Company by specific reference in such a filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits. The following exhibit is furnished as part of this Report on Form 8-K:

Exhibit No.	Description of Exhibit
99.1	Press Release dated May 26, 2017

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.

ADAPTIMMUNE THERAPEUTICS PLC

Date: May 26, 2017

By: /s/ Margaret Henry
Name: Margaret Henry
Title: Corporate Secretary

3

Exhibit Index

<u>Exhibit No.</u>	<u>Description of Exhibit</u>
99.1	Press Release dated May 26, 2017

4



Adaptimmune Announces an Oral Presentation and Four Trials in Progress Posters at the American Society of Clinical Oncology (ASCO) Annual Meeting

PHILADELPHIA, Pa. and OXFORD, UK., May 26, 2017 — Adaptimmune Therapeutics plc (Nasdaq: ADAP), a leader in T-cell therapy to treat cancer, today announced an oral presentation, as well as four trials in progress posters, at the 2017 ASCO annual meeting in Chicago, Illinois on June 2 through June 6, 2017.

During an oral presentation scheduled for 1:15-1:27 PM CDT on June 5th, Dr. Sandra P. D'Angelo of the Memorial Sloan Kettering Cancer Center will present a full update on Cohorts 1, 2, 3, and 4 from Adaptimmune's ongoing study of NY-ESO SPEAR T-cells in patients with synovial sarcoma.

The Company will host a webinar / teleconference on June 6th from 8:00—9:00 AM EDT (1:00 -2:00 PM BST) to discuss this updated synovial sarcoma clinical data. Call in details and the webinar link will be made available in the Investors section of Adaptimmune's website (<http://www.adaptimmune.com>), and will also be provided in a subsequent ASCO press release on June 5th.

The four trials in progress posters will summarize the study designs for Adaptimmune's ongoing NY-ESO trials in myxoid/round cell liposarcoma (MRCLS), ovarian cancer, and non-small cell lung cancer (NSCLC); the Company's ongoing MAGE-A10 trial in NSCLC, and its MAGE-A10 triple tumor study in patients with head and neck, melanoma, or urothelial "bladder" tumors.

Adaptimmune will also host a corporate exhibition booth in the Oncology Professionals Hall (Booth #5031).

Details regarding the oral presentation and the four trials in progress posters are as follows:

Oral Presentation:

Monday, June 5, 2017

Session: Developmental Therapeutics—Immunotherapy

- Abstract ID: 3000
 - Title: "Open label, non-randomized, multi-cohort pilot study of genetically engineered NY-ESO-1 specific NY-ESO-1c259t in HLA-A2+ patients with synovial sarcoma (NCT01343043)"
 - Presentation Time: 1:15-1:27 PM CDT
 - Location: Hall D1

Trials in Progress Posters:

Monday, June 5, 2017

Session: Developmental Therapeutics—Immunotherapy

Presentation Time: 8:00-11:30 AM CDT

Location: Hall A

- Abstract ID: TPS3094
 - Poster Board #: 187b
 - Title: "A phase I/IIa, open-label, clinical trial evaluating the safety and efficacy of autologous T-cells expressing enhanced T-cell receptors (TCRs) specific for NY-ESO-1 in patients with recurrent or treatment refractory ovarian cancer (NCT01567891)"
-
- Abstract ID: TPS3097
 - Poster Board #: 189a
 - Title: "A pilot study of NY-ESO-1^{c259} T-cells in subjects with advanced myxoid/round cell liposarcoma (NCT02992743)"
 - Abstract ID: TPS3096
 - Poster Board #: 188b
 - Title: "Two phase I/II open-label clinical trials evaluating the safety and efficacy of autologous T-cells expressing enhanced TCRs specific for NY-ESO-1 or MAGE-A10 in subjects with stage IIIb or stage IV non-small cell lung cancer (NCT02588612/NCT02592577)"
 - Abstract ID: TPS3098
 - Poster Board #: 189b
 - Title: "A phase I single-arm, open-label clinical trial evaluating safety of MAGE-A10c796T in subjects with advanced or metastatic head and neck, melanoma, or urothelial tumors (NCT02989064)"

About Adaptimmune

Adaptimmune is a clinical-stage biopharmaceutical company focused on the development of novel cancer immunotherapy products. The Company's unique SPEAR (Specific Peptide Enhanced Affinity Receptor) T-cell platform enables the engineering of T-cells to target and destroy cancer, including solid tumors. Adaptimmune has a number of proprietary clinical programs, and is also developing its NY-ESO SPEAR T-cell program under a strategic collaboration and licensing agreement with GlaxoSmithKline. The Company is located in Philadelphia, USA and Oxfordshire, U.K. For more information, please visit <http://www.adaptimmune.com>

Forward-Looking Statements

This release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 (PSLRA). These forward-looking statements involve certain risks and uncertainties. Such risks and uncertainties could cause our actual results to differ materially from those indicated by such forward-looking statements, and include, without limitation: the success, cost and timing of our product development activities and clinical trials and our ability to successfully advance our TCR therapeutic candidates through the regulatory and commercialization processes. For a further description of the risks and uncertainties that could cause our actual results to differ materially from those expressed in these forward-looking statements, as well as risks relating to our business in general, we refer you to our Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (SEC) on May 10, 2017, and our other SEC filings. The forward-looking statements contained in this press release speak only as of the date the statements were made and we do not undertake any obligation to update such forward-looking statements to reflect subsequent events or

circumstances.

Adaptimmune Contacts

Investor Relations

Juli P. Miller, Ph.D.

T: (215) 825-9310

E: juli.miller@adaptimmune.com

Media Relations

Margaret Henry

T: +44 (0)1235 430036

Cell: +44 (0)7710 304249

E: margaret.henry@adaptimmune.com
